PBYI — Puma Biotechnology Inc
Is PBYI overbought or oversold? Here is the current MarketMoodz read.
Puma Biotechnology Inc (PBYI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $7.34. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$7.34
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Puma Biotechnology Inc (PBYI) is a small oncology company with a concentrated product portfolio and growth largely dependent on successful clinical/regulatory progress or strategic partnerships. Competitive intensity in HER2 and oncology treatments, combined with constrained financial flexibility, creates meaningful execution risk. Market sentiment is currently favoring larger, defensive pharma names, reducing near‑term investor appetite for single‑asset biotechs. Key short‑term catalysts include trial readouts, regulatory updates, and financing decisions; adverse outcomes on any of these fronts could materially depress equity value. Monitor cash runway, upcoming clinical timelines, and any partnership/licensing activity as primary determinants of future trajectories.
Key factors
- Concentrated commercial profile tied to a small set of oncology assets; limited diversification of revenue streams
- Intense competitive pressure in HER2 and oncology spaces from larger pharma names and newer ADCs/targeted therapies
- Near‑term growth dependent on clinical readouts, label expansions, or partnering/licensing deals that are uncertain in timing
- Market environment favoring large‑cap pharma defensives reduces appetite for small, single‑asset biotech stories
- Balance‑sheet constraints and historical cash burn increase likelihood of dilution or need for non‑dilutive financing
- Potential for short‑term volatility around earnings, trial updates, or financing announcements
Risks
- Clinical trial setbacks or regulatory denials that could materially reduce commercial prospects
- Rapid competitive displacement by more effective or better‑tolerated therapies leading to loss of market share
- Need to raise capital via equity or convertible instruments, causing shareholder dilution and downward price pressure
- Reimbursement or pricing headwinds in oncology that compress revenue expectations
- Low liquidity and elevated volatility amplifying price moves on newsflow
- Sectorwide financing dynamics (convertible‑debt/hedging pressure) that can increase selling pressure on mid‑cap biotech names
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for PBYI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.